Literature DB >> 14702521

Successful allogeneic leg transplantation in rats in conjunction with intra-bone marrow injection of donor bone marrow cells.

Takashi Esumi1, Muneo Inaba, Naoya Ichioka, Taketoshi Kushida, Hirokazu Iida, Susumu Ikehara.   

Abstract

BACKGROUND: We have recently established a new method for bone marrow transplantation (BMT) in mice: bone marrow cells are directly injected into the intra-bone marrow (IBM) cavity. IBM-BMT induces persistent donor-specific tolerance and enhances the rapid recovery or reconstitution of the hematolymphoid system of donor origin without any signs of graft-versus-host disease (GVHD) or graft failure. Furthermore, the prior injection of fludarabine can reduce the irradiation dose to the sublethal level (4.5 Gy x 2). Therefore, we hypothesize that IBM-BMT plus fludarabine is applicable to allogeneic leg transplantation in rats.
METHODS: Brown Norway (BN; RT1An) rats were injected intravenously with 50 mg/kg of fludarabine phosphate, followed by sublethal fractionated irradiation (4.5 Gy x 2) 1 day before IBM-BMT. The hind limbs from Fischer 344 (F344; RT1Al) rats were transplanted on day 0, and bone marrow cells (3 x 10(7) cells/50 microL) obtained from the donor F344 rats were injected into the bone marrow cavity of the left tibias of the recipient BN rats.
RESULTS: The hematolymphoid cells in the recipient BN rats were completely reconstituted by the cells of the donor F344 rats. The limbs transplanted from the donor F344 rats were accepted for >1 year without any clinical signs of rejection (10 of 10). The lymphocytes of the BN rats showed tolerance to both donor-type and recipient-type major histocompatibility complex determinants in mixed lymphocyte reaction, but showed a significant response to the third-party major histocompatibility complex determinants.
CONCLUSIONS: Using a combination of the injection of fludarabine, low-dose irradiation, and IBM-BMT, we have succeeded in allogeneic limb transplantation without using any immunosuppressants after the operation. This strategy would be applicable to the transplantation of other vascularized organs in humans.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14702521     DOI: 10.1097/01.TP.0000081945.23698.5D

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  4 in total

Review 1.  The future of stem cell transplantation in autoimmune disease.

Authors:  Susumu Ikehara
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

2.  Treatment of streptozotocin-induced diabetes mellitus in mice by intra-bone marrow bone marrow transplantation plus portal vein injection of beta cells induced from bone marrow cells.

Authors:  M Li; M Inaba; K Q Guo; H Hisha; N G Abraham; S Ikehara
Journal:  Int J Hematol       Date:  2007-12       Impact factor: 2.490

Review 3.  Intractable diseases treated with intra-bone marrow-bone marrow transplantation.

Authors:  Ming Li; Kuquan Guo; Susumu Ikehara
Journal:  Front Cell Dev Biol       Date:  2014-09-02

4.  Histological Architecture Underlying Brain-Immune Cell-Cell Interactions and the Cerebral Response to Systemic Inflammation.

Authors:  Atsuyoshi Shimada; Sanae Hasegawa-Ishii
Journal:  Front Immunol       Date:  2017-01-19       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.